Dear Pharmaceutical Professional,
The myelodysplastic syndrome (MDS) market will be impacted by data presented during the virtual American Society of Hematology (ASH) meeting. With this year’s new virtual format, do you have a strategy for understanding the commercial impact of breaking data in MDS?
As seasoned experts in bringing congress data to hematologists/oncologists in their practice, our team will be working with 30 hem/oncs during the meeting to better understand the commercial implications of data presented for:
- magrolimab + azacitidine
- pevonedistat + azacitidine vs. azacitidine
- venetoclax + azacitidine
- azacitidine + pembrolizumab
- sabatolimab (MBG453)
- nivolumab + ipilimumab with or without azacitidine
Order your 60-slide report so you can make better decisions today and prepare for tomorrow.
The Breaking Data Team